Ulcerative Colitis Clinical Trial
Official title:
A Randomized, Double-Blind, Parallel-Group, Single-Ascending Dose, Placebo-Controlled Safety and Tolerability Study of PUR 0110 Rectal Enema in Normal Healthy Volunteers
This is a first-in-man study of a novel investigational botanical drug complex, PUR 0110
rectal enema, that has been shown to have potent anti-inflammatory, antioxidant and
immunomodulatory effects following in vitro and in vivo pharmacology studies, to assess the
safety and tolerability of sequential single-ascending doses in normal healthy volunteers
and to determine the maximum tolerated dose (MTD). As a tertiary objective, the study will
also investigate the presence of specific pharmacokinetic markers following the
administration of single-dose PUR 0110 at each dose level.
The study is designed as a single-center, randomized, double-blind, parallel-group,
sequential single-ascending dose, placebo-controlled safety, tolerability and
pharmacokinetic study of PUR 0110 rectal enema in 24 normal healthy male volunteers.
Eligible subjects will be randomly assigned to 4 Cohorts of 6 subjects each to receive
active drug (PUR 0110 Enema) or placebo enema as follows: 187.5 mg/60 g - Cohort 1, 375
mg/60 g - Cohort 2, 750 mg/60 g - Cohort 3 or 1500 mg/60 g - Cohort 4. Within each Cohort,
subjects will be randomized in a 2:1 ratio to receive either active treatment (PUR 0110
enema; n = 4) or placebo enema (n = 2). Each subject will receive only 1 dose of assigned
study medication and dosing of subjects within each cohort will also be by sequential
inclusion.
Status | Completed |
Enrollment | 24 |
Est. completion date | August 2009 |
Est. primary completion date | August 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Healthy adult non-smoking male volunteers between the ages of 18 to 55 years, inclusive. - Must provide a voluntary written informed consent prior to initiation of screening, must be capable of following the verbal and written study instructions, and be able to commit to any confinements and return visits during the entire period of the study. - Must have a body mass index (BMI) that is within 18 to 30 kg/m2 on the BMI Chart. - Must have a normal digital rectal examination at screening. - Must have normal colonic and rectal mucosa at the baseline flexible sigmoidoscopy (i.e., no bleeding, inflammation, edema, ulceration or other abnormal finding). - Must have no clinically significant abnormal findings in their medical history, physical examination or clinical laboratory test results. Exclusion Criteria: - History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, or psychiatric disease. - History of allergic reaction or hypersensitivity to spinach, spinach tablet, spinach powder or spinach extract; and to latex, molds and mushrooms. - Subjects with abnormal digital rectal examination at screening - Subjects with abnormal colonic and rectal mucosa at the baseline flexible sigmoidoscopy i.e., have bleeding, inflammation, edema or ulceration or other abnormal finding. - Subjects who used NSAIDs within 14 days prior to dosing. - History of pseudoallergic hypersensitivity to the food color additives, tartrazine (E102) and sunset yellow (E110), allergic asthma, aspirin intolerance, and severe or multiple allergies. - History of gout, pseudogout or hyperuricemia. - History of kidney stones. - Past medical history of significant colonic surgery, except for benign polyp removal. - Subjects with anatomical abnormalities of the colon, e.g., short bowel or other abnormalities. - Subjects with a history of rectal bleeding, passage of mucus rectally, and irregular bowel habits, e.g., frequent diarrhea or constipation. - Subjects with internal or external hemorrhoids. - History or presence of alcoholism or drug abuse within the past 2 years. - Subjects with a current history of smoking. If a former smoker, must have stopped smoking for at least 3 months to qualify for study entry. - Subjects who tested positive at screening for HIV, HbsAg or HCV. - Subjects who used any prescription medications within 14 days prior to dosing. - Subjects who used any rectal enema or laxative within 7 days prior to dosing. - Subjects who used any over-the-counter (OTC) medications within 7 days prior to dosing. - Subjects who have made a donation of blood or blood products (with the exception of plasma as noted below) within 56 days prior to dosing. - Subjects who have made a plasma donation within 7 days prior to dosing. - Subjects with hemoglobin less than 14.0 g/dl. - Subjects who participated in another clinical trial within 28 days prior to dosing. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | FOCUS Clinical Drug Development GmbH Phase 1 Clinic | Neuss |
Lead Sponsor | Collaborator |
---|---|
PurGenesis Technologies Inc. |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence, nature and severity of adverse events and abnormal clinical laboratory test results | After single-ascending doses | Yes | |
Secondary | Maximum tolerated dose (MTD) | After single-ascending doses | Yes | |
Secondary | Pharmacokinetic profile and parameters - if specific pharmacokinetic markers are successfully identified | After single-ascending doses | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |